Ivan John Clement
@iclement07
Followers
155
Following
560
Media
19
Statuses
812
Data Strategist, AI/ML Scientist, Innovator, Digital Health Enthusiast | Big data for better health | Roche, IQVIA, Merck, MIT
Basel, Switzerland
Joined November 2013
An interesting and much-needed development - such a "mechanism-driven" framework for MS is reminiscent of how oncology treatment decisions are more and more based on cancer genomic profiles. This, I believe, is but a stepping stone towards a future with m…
0
0
3
I am blessed to have shared these past 3 days of energizing and insightful #medical and #realworldevidence discussions at the #ectrims2022 #medicalcongress with my 3-month old son. Reading #neurology to him is currently the best way to make him fall aslee…
0
0
0
RT @andy_fitze: #AI & #Data - How to Make the Marriage Work.Phase #2: From Engagement to Marriage 💍➡️🗓️🧝🏻♀️🎊🎉❤️. In the spotlight: AI-driv….
0
7
0
Indeed - when there’s enough “pressure”, we can find ways to shorten the whole drug/vaccine dev process without sacrificing on quality!.
This will go down in history as one of science and medical research's greatest achievements. Perhaps the most impressive. I put together a preliminary timeline of some key milestones to show how several years of work were compressed into months.
0
0
0
RT @AndrewLBeam: Are we making meaningful progress on machine learning for EHR data?. New preprint with @DavidRBellamy and Leo Celi tries….
0
74
0
RT @AndreaCoravos: I'm excited to announce. we're unveiling a landmark collaboration, 𝑇ℎ𝑒 𝑃𝑙𝑎𝑦𝑏𝑜𝑜𝑘, the essential how-to guide to develop….
0
30
0
RT @RWDinsights: Take the competitive advantage of applying machine learning to small data sets. Paired with deep human knowledge, could be….
0
7
0
Good to see the developments in the #digital #endpoints space for #pharma! Give it a few more years and we won’t be able to imagine a world where clinical trials won’t have such!.
30+ pharma companies have submitted a digital endpoint to regulators to support a primary, secondary, or label claim. This tech isn't "exploratory" anymore. It's core to drug development. Welcome to the world of decentralized clinical trials. 🚀.
0
0
1
RT @BillGates: Humankind has never had a more urgent task than creating broad immunity for coronavirus. It’s going to require a global coop….
0
6K
0
“In broad terms, an agile organization is one that combines a stable backbone of core processes and capabilities with a high degree of flexibility for rapid response to change.”. And data+analytics can help in the agile transformat…
0
0
0
“Alphabet’s Google will bring its artificial-intelligence and cloud-computing capabilities to a new partnership with pharma giant Sanofi. The project is aimed at accelerating the discovery of new medicines, increasing the understa…
0
0
0
“How do [different clinical] specialties work together with primary care around the A1C and not only slow the progression of diabetes, but also the complications and comorbidities that are exacerbated by their diabetes? . that is…
0
0
0
Atomwise incorporates protein structure data in its analysis to not only identify promising compounds from known libraries, but also to make predictions for virtually synthesized novel molecules that have never physically existed.…
0
0
0
Sounds a lot like OHDSI (i.e. in the observational/real-world evidence space), but for pharma drug discovery!. “MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery) project. aims, for the first time, to use machine…
0
0
0
Cool study with deep multi-omics data enabling the investigation of early molecular signs of diabetes progression at an individual level!
0
0
0
Wow exciting stuff for an MNC pharma to open a global HQ in China!. “In his opening speech, Group President Michael Goettler stressed the significance of this historic moment. ’Basing our global headquarters in China will enable u…
0
0
0
When asked to identify the greatest challenge facing their #translationalmedicine (TM) groups, 76% of respondents pointed to the difficulty in defining clear metrics to measure long-term success, given the additive impact of TM activities on the overall R…
0
0
0
When asked to identify the greatest challenge facing their #translationalmedicine (TM) groups, 76% of respondents pointed to the difficulty in defining clear metrics to measure long-term success, given the additive impact of TM act…
0
0
0